Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$45.23
+$1.63 · +3.74%
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Previous close
$45.23
+$1.63 · +3.74%
After-hours
$45.23
$0.00 · 0.00%
Oct 9, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Day range
Current $45.23
52-week range
Current $45.23
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
37
Expensive
Sentiment
60
Mixed
Risk
47
Elevated Risk
Momentum
69
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Day range
Current $45.23
52-week range
Current $45.23
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 517.15M USD | 445.76M USD | 361.05M USD | 296.54M USD | 219.51M USD |
| Cost of goods sold | 157.1M USD | 147.62M USD | 112.9M USD | 101.58M USD | 74.4M USD |
| Gross profit | 360.05M USD | 298.15M USD | 248.15M USD | 194.95M USD | 145.11M USD |
| Research and development | 70.81M USD | 69.29M USD | 57.31M USD | 40.6M USD | 29.84M USD |
| Selling, general, and administrative | 210.95M USD | 206.04M USD | 184.23M USD | 174.08M USD | 181.19M USD |
| Operating expenses | 285.9M USD | 282M USD | 333.94M USD | 236.04M USD | 227.02M USD |
| Interest income | — | 11.15M USD | 7.34M USD | 1.97M USD | 135K USD |
| Interest expense | — | 2K USD | 15K USD | 198K USD | 241K USD |
| Depreciation and amortization | 21.42M USD | 23.46M USD | 27.19M USD | 25.93M USD | 19.59M USD |
| Operating income | 74.15M USD | 16.14M USD | −85.8M USD | −41.08M USD | −81.9M USD |
| Net income | 66.35M USD | 24.14M USD | −74.4M USD | −36.56M USD | −75.56M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$57.43
26.97% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.